Emergent BioSolutions (NYSE:EBS) Raised to “Buy” at StockNews.com

Emergent BioSolutions (NYSE:EBS) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report released on Monday.

Several other equities research analysts have also recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Benchmark raised their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Price Performance

Shares of EBS traded up $0.20 during trading hours on Monday, reaching $9.70. 695,038 shares of the company traded hands, compared to its average volume of 890,394. The stock has a market capitalization of $525.28 million, a PE ratio of -2.36 and a beta of 1.62. The stock has a fifty day simple moving average of $9.71 and a 200 day simple moving average of $9.12. Emergent BioSolutions has a fifty-two week low of $1.48 and a fifty-two week high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Institutional Trading of Emergent BioSolutions

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. purchased a new stake in Emergent BioSolutions during the third quarter valued at about $1,547,000. Oak Hill Advisors LP acquired a new position in shares of Emergent BioSolutions in the 3rd quarter valued at about $9,296,000. Assenagon Asset Management S.A. grew its holdings in shares of Emergent BioSolutions by 74.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after purchasing an additional 316,700 shares during the period. Barclays PLC grew its holdings in shares of Emergent BioSolutions by 361.6% during the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 30,792 shares during the period. Finally, Geode Capital Management LLC increased its position in Emergent BioSolutions by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock worth $4,861,000 after purchasing an additional 25,776 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.